MX2010009222A - Soluciones farmaceuticas, proceso de preparacion y usos terapeuticos. - Google Patents

Soluciones farmaceuticas, proceso de preparacion y usos terapeuticos.

Info

Publication number
MX2010009222A
MX2010009222A MX2010009222A MX2010009222A MX2010009222A MX 2010009222 A MX2010009222 A MX 2010009222A MX 2010009222 A MX2010009222 A MX 2010009222A MX 2010009222 A MX2010009222 A MX 2010009222A MX 2010009222 A MX2010009222 A MX 2010009222A
Authority
MX
Mexico
Prior art keywords
preparation
therapeutic uses
pharmaceutical solutions
pharmaceutical
solutions
Prior art date
Application number
MX2010009222A
Other languages
English (en)
Inventor
Eric Schenkel
Claire Poulain
Bertrand Dodelet
Domenico Fanara
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39643757&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010009222(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of MX2010009222A publication Critical patent/MX2010009222A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente invención se relaciona con una solución farmacéutica estable, un proceso de preparación de la misma y usos terapéuticos de la misma.
MX2010009222A 2008-03-03 2009-03-02 Soluciones farmaceuticas, proceso de preparacion y usos terapeuticos. MX2010009222A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08003915 2008-03-03
PCT/EP2009/052454 WO2009109547A1 (en) 2008-03-03 2009-03-02 Pharmaceutical solutions, process of preparation and therapeutic uses

Publications (1)

Publication Number Publication Date
MX2010009222A true MX2010009222A (es) 2010-09-28

Family

ID=39643757

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009222A MX2010009222A (es) 2008-03-03 2009-03-02 Soluciones farmaceuticas, proceso de preparacion y usos terapeuticos.

Country Status (21)

Country Link
US (1) US20110021786A1 (es)
EP (1) EP2273975B8 (es)
JP (6) JP2011513360A (es)
KR (1) KR101353425B1 (es)
CN (1) CN101945647B (es)
AU (1) AU2009221177B2 (es)
BR (1) BRPI0908421C1 (es)
CA (1) CA2715685C (es)
CY (1) CY1115254T1 (es)
DK (1) DK2273975T3 (es)
EA (1) EA018736B1 (es)
ES (1) ES2474945T3 (es)
HK (1) HK1148202A1 (es)
HR (1) HRP20140634T1 (es)
IL (1) IL207558A (es)
MX (1) MX2010009222A (es)
PL (1) PL2273975T3 (es)
PT (1) PT2273975E (es)
RS (1) RS53418B (es)
SI (1) SI2273975T1 (es)
WO (1) WO2009109547A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2474945T3 (es) * 2008-03-03 2014-07-10 Ucb Pharma, S.A. Soluciones farmacéuticas, procedimiento de preparación y usos terapéuticos
JP5917148B2 (ja) * 2008-10-16 2016-05-11 ザ ジョーンズ ホプキンズ ユニバーシティＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ 認知機能を改善するための方法および組成物
LT3372605T (lt) 2008-10-22 2022-02-10 Array Biopharma, Inc. Pakeistieji pirazolo[1,5-a]pirimidino junginiai, kaip trk kinazės inhibitoriai
JP5954889B2 (ja) * 2008-11-18 2016-07-20 ユセベ ファルマ ソシエテ アノニム ２−オキソ−１−ピロリジン誘導体を含む持続放出製剤
ES2568075T3 (es) 2011-12-16 2016-04-27 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Composición farmacéutica que comprende (S)-2-(2-oxopirrolidin-1-il)butanamida
CN102525900A (zh) * 2012-01-19 2012-07-04 南京恒道医药科技有限公司 左乙拉西坦注射液及其制备方法
AU2013249034B2 (en) * 2012-04-19 2016-04-28 C. R. Bard, Inc. Infusates with enhanced pH stability under ethylene oxide sterilization
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP3827820A1 (en) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam for improving cognitive function
ES2881081T3 (es) 2013-03-15 2021-11-26 Agenebio Inc Procedimientos y composiciones para mejorar la función cognitiva
CN103550143B (zh) * 2013-10-19 2019-05-14 浙江华海药业股份有限公司 一种左乙拉西坦注射液的制备方法
US10925834B2 (en) 2015-05-22 2021-02-23 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
BR112018012870A2 (pt) 2015-12-30 2018-12-04 Adamas Pharmaceuticals Inc métodos e composições para o tratamento de transtornos relacionados à crise
RU2751767C2 (ru) 2016-04-04 2021-07-16 Локсо Онколоджи, Инк. Жидкие составы (s)-n-(5-((r)-2-(2,5-дифторфенил)пирролидин-1-ил)пиразоло[1,5-a]пиримидин-3-ил)-3-гидроксипирролидин-1-карбоксамида
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
EP3800189B1 (en) 2016-05-18 2023-06-28 Loxo Oncology, Inc. Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
CN106491523A (zh) * 2016-09-24 2017-03-15 北京万全德众医药生物技术有限公司 一种布瓦西坦口服溶液及其制备方法
WO2020021372A1 (en) * 2018-07-24 2020-01-30 Zenvision Pharma Llp Nasal drug delivery system of brivaracetam or salt thereof thereof
US20210393588A1 (en) * 2018-11-02 2021-12-23 Zenvision Pharma Llp Ready to use intravenous infusion of brivaracetam or salt thereof
EP3951452A4 (en) 2019-03-28 2022-12-28 Toyobo Co., Ltd. ANTI-REFLECTIVE CIRCULAR POLARIZER AND IMAGE DISPLAY DEVICE THEREOF
CN113908120A (zh) * 2021-09-30 2022-01-11 北京诺康达医药科技股份有限公司 布立西坦药物溶液及其制备方法
CN114213306A (zh) * 2021-12-28 2022-03-22 海南鑫开源医药科技有限公司 一种布瓦西坦酸杂质的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
CN1964942A (zh) * 2004-06-11 2007-05-16 Ucb股份有限公司 通过分子内烯丙基化制备2－氧代－1－吡咯烷衍生物的方法
EP1731149A1 (en) * 2005-06-08 2006-12-13 Ucb S.A. Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
ES2474945T3 (es) * 2008-03-03 2014-07-10 Ucb Pharma, S.A. Soluciones farmacéuticas, procedimiento de preparación y usos terapéuticos
KR101286540B1 (ko) * 2008-04-16 2013-07-17 엘지디스플레이 주식회사 액정표시장치

Also Published As

Publication number Publication date
JP2020128384A (ja) 2020-08-27
HK1148202A1 (en) 2011-09-02
JP2015145382A (ja) 2015-08-13
RS53418B (en) 2014-12-31
JP2019089837A (ja) 2019-06-13
CA2715685A1 (en) 2009-09-11
PT2273975E (pt) 2014-07-17
EP2273975B1 (en) 2014-04-09
EP2273975A1 (en) 2011-01-19
WO2009109547A1 (en) 2009-09-11
AU2009221177B2 (en) 2013-05-30
CN101945647A (zh) 2011-01-12
PL2273975T3 (pl) 2014-09-30
IL207558A0 (en) 2010-12-30
JP2017114890A (ja) 2017-06-29
HRP20140634T1 (hr) 2014-11-21
KR101353425B1 (ko) 2014-02-18
BRPI0908421B1 (pt) 2020-08-04
BRPI0908421C1 (pt) 2021-05-25
JP2022169734A (ja) 2022-11-09
IL207558A (en) 2015-02-26
US20110021786A1 (en) 2011-01-27
EP2273975B8 (en) 2014-12-17
EA201001402A1 (ru) 2011-06-30
KR20100126466A (ko) 2010-12-01
CA2715685C (en) 2015-04-28
CY1115254T1 (el) 2017-01-04
SI2273975T1 (sl) 2014-09-30
AU2009221177A1 (en) 2009-09-11
CN101945647B (zh) 2013-01-09
JP2011513360A (ja) 2011-04-28
BRPI0908421A2 (pt) 2015-08-04
BRPI0908421B8 (pt) 2020-08-18
DK2273975T3 (da) 2014-06-30
ES2474945T3 (es) 2014-07-10
EA018736B1 (ru) 2013-10-30

Similar Documents

Publication Publication Date Title
HK1148202A1 (en) Pharmaceutical solutions, process of preparation and therapeutic uses
MX2011002966A (es) Formas de dosificacion farmaceutica que comprenden poli (e-caprolactona).
PH12013502192A1 (en) Antibodies against human angiopoietin 2
HK1140940A1 (en) Titration of tapentadol
WO2010087947A3 (en) Transdermal delivery of diclofenac, carbamazepine and benzydamine
IN2012DN02805A (es)
MX2011007930A (es) Conjugados de insulina cristalina.
MX2012001974A (es) Compuestos de biarilo y metodos de uso de los mismos.
IN2014CN02616A (es)
SG171542A1 (en) Pharmaceutical composition comprising a strontium salt, vitamin d and a cyclodextrin
ZA200906853B (en) Aqueous hydrogen peroxide solution, process for its preparation and use thereof
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
TW200942524A (en) Novel aminomethyl benzene derivatives
TW200942530A (en) Pyridine compounds
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MX349563B (es) Formulacion farmaceutica de fenofibrato nanonizado.
MX2009008108A (es) Composicion farmaceutica que contiene una combinacion de tramadol y ketoprofeno.
IL211062A0 (en) Pharmaceutical uses of lanosta-8,24-dien-3-ols
UA96574C2 (ru) Использование ивабрадина для получения лекарств, предназначенных для лечения эндотелиальной дисфункции
UA89010C2 (ru) Комбинированное обезболивающее средство на основе кеторолака и дротаверина
WO2010139411A3 (de) 17β-ALKYL-17α-OXY-ESTRATRIENE
UA92646C2 (ru) применение производных 2-оксоиндолин-3-глиоксиловой кислоты в качестве средств с актопротекторным действием
UA48243U (uk) Фармацевтична композиція
UA35660U (en) Use of antihomotoxic preparations as cytoprotectors
JO2775B1 (en) 3-indazolil 4-pyridyl isothiazole

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: UCB BIOPHARMA SPRL